Peregrine Pharmaceuticals (CDMO) vs. Its Rivals Head to Head Survey

Peregrine Pharmaceuticals (NASDAQ: CDMO) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Peregrine Pharmaceuticals to related companies based on the strength of its risk, profitability, earnings, institutional ownership, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations for Peregrine Pharmaceuticals and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Peregrine Pharmaceuticals 0 0 1 0 3.00
Peregrine Pharmaceuticals Competitors 158 828 1815 61 2.62

Peregrine Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 166.67%. As a group, “Biopharmaceuticals” companies have a potential upside of 2.87%. Given Peregrine Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Peregrine Pharmaceuticals is more favorable than its peers.

Risk & Volatility

Peregrine Pharmaceuticals has a beta of 2.73, meaning that its share price is 173% more volatile than the S&P 500. Comparatively, Peregrine Pharmaceuticals’ peers have a beta of 1.10, meaning that their average share price is 10% more volatile than the S&P 500.


This table compares Peregrine Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Peregrine Pharmaceuticals -39.23% -52.55% -24.77%
Peregrine Pharmaceuticals Competitors -13,485.92% -53.67% -24.24%

Insider & Institutional Ownership

18.7% of Peregrine Pharmaceuticals shares are held by institutional investors. Comparatively, 42.7% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 2.5% of Peregrine Pharmaceuticals shares are held by company insiders. Comparatively, 15.3% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Peregrine Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Peregrine Pharmaceuticals $57.63 million -$28.15 million -5.36
Peregrine Pharmaceuticals Competitors $584.27 million $101.79 million 60.94

Peregrine Pharmaceuticals’ peers have higher revenue and earnings than Peregrine Pharmaceuticals. Peregrine Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


Peregrine Pharmaceuticals peers beat Peregrine Pharmaceuticals on 7 of the 13 factors compared.

About Peregrine Pharmaceuticals

Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., incorporated on September 25, 1996, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.

Receive News & Ratings for Peregrine Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply